{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:25:34Z","timestamp":1780323934307,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) is the main indication for autologous stem cell transplantation (ASCT). Novel supportive therapies (e.g., granulocyte colony-stimulating factor) have significantly improved post-ASCT-related mortality; however, data on biosimilar pegfilgrastim-bmez (BIO\/PEG) in this setting is lacking. This prospective cohort study compared Italian patients with MM who received BIO\/PEG post-ASCT with data collected retrospectively from historical control groups from the same center who received either filgrastim-sndz (BIO\/G-CSF) or pegfilgrastim (PEG; originator). The primary endpoint was time to neutrophil engraftment (three consecutive days with an absolute neutrophil count \u2265 0.5 \u00d7 10<jats:sup>9<\/jats:sup>\/L). Secondary endpoints included incidence and duration of febrile neutropenia (FN). Of the 231 patients included, 73 were treated with PEG, 102 with BIO\/G-CSF, and 56 with BIO\/PEG. Median age was 60 years and 57.1% were male. Neutrophil engraftment was reached after a median of 10 days in the BIO\/PEG and PEG groups and 11 days in the BIO\/G-CSF group. Among patients who achieved neutrophil engraftment earlier than this (i.e., day 9), 58% (29\/50) were on PEG; of those who achieved it later (i.e., day 11), 80.8% (59\/73) were on BIO\/G-CSF. FN incidence was higher with BIO\/G-CSF (61.4%) versus PEG (52.1%) or BIO\/PEG (37.5%) (<jats:italic>p<\/jats:italic> = 0.02 among groups). Patients on BIO\/PEG had less frequent grade 2\u20133 diarrhea (5.5%) compared with BIO\/G-CSF (22.5%) or PEG (21.9%); grade 2\u20133 mucositis was most frequent in the BIO\/G-CSF group. In conclusion, pegfilgrastim and its biosimilar displayed an advantageous efficacy and safety profile compared with biosimilar filgrastim in patients with MM post-ASCT.<\/jats:p>","DOI":"10.1007\/s00277-023-05228-z","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T19:33:54Z","timestamp":1682019234000},"page":"1915-1925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-419X","authenticated-orcid":false,"given":"Massimo","family":"Martino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0081-3549","authenticated-orcid":false,"given":"Mercedes","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetana","family":"Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pellicano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Verduci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo Antonio","family":"Canale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Loteta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Moscato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Alati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Consuelo","family":"Ieracitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Cuzzocrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Altomonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Florenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Irrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Naso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Console","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Imbalzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3580-4602","authenticated-orcid":false,"given":"Giovanni","family":"Tripepi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7768-3925","authenticated-orcid":false,"given":"Annalisa","family":"Pitino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"5228_CR1","unstructured":"Auletta JJ, Kou J, Chen M, Shaw BE (2021) Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides. https:\/\/www.cibmtr.org\/ReferenceCenter\/SlidesReports\/SummarySlides\/pages\/index.aspx. Accessed 12 December 2022"},{"key":"5228_CR2","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s41409-022-01604-x","volume":"57","author":"JR Passweg","year":"2022","unstructured":"Passweg JR, Baldomero H, Chabannon C, Corbacioglu S, de la C\u00e1mara R, Dolstra H et al (2022) Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplant 57:742\u2013752. https:\/\/doi.org\/10.1038\/s41409-022-01604-x","journal-title":"Bone Marrow Transplant"},{"key":"5228_CR3","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00277-019-03663-5","volume":"98","author":"M Blanes","year":"2019","unstructured":"Blanes M, Lorenzo JI, Ribas P, Jim\u00e9nez A, Gonz\u00e1lez JD, Cejalvo MJ et al (2019) Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma. Ann Hematol 98:2013\u20132015. https:\/\/doi.org\/10.1007\/s00277-019-03663-5","journal-title":"Ann Hematol"},{"key":"5228_CR4","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/bmt.2016.94","volume":"51","author":"M Martino","year":"2016","unstructured":"Martino M, Tripepi G, Messina G, Vincelli ID, Console G, Recchia AG et al (2016) A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy. Bone Marrow Transplant 51:1197\u20131203. https:\/\/doi.org\/10.1038\/bmt.2016.94","journal-title":"Bone Marrow Transplant"},{"key":"5228_CR5","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.bbmt.2015.06.011","volume":"21","author":"M Musso","year":"2015","unstructured":"Musso M, Messina G, Marcacci G, Crescimanno A, Console G, Donnarumma D et al (2015) High-dose melphalan plus thiotepa as conditioning regimen before second autologous stem cell transplantation for \"de novo\" multiple myeloma patients: a phase II study. Biol Blood Marrow Transplant 21:1932\u20131938. https:\/\/doi.org\/10.1016\/j.bbmt.2015.06.011","journal-title":"Biol Blood Marrow Transplant"},{"key":"5228_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood-2009-06-229658","volume":"115","author":"M Roussel","year":"2010","unstructured":"Roussel M, Moreau P, Huynh A, Mary JY, Danho C, Caillot D et al (2010) Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 115:32\u201337. https:\/\/doi.org\/10.1182\/blood-2009-06-229658","journal-title":"Blood"},{"key":"5228_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.clml.2015.02.024","volume":"15","author":"VR Bhatt","year":"2015","unstructured":"Bhatt VR, Loberiza FR Jr, Jing H, Bociek RG, Bierman PJ, Maness LJ et al (2015) Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades. Clin Lymphoma Myeloma Leuk 15:409\u201315.e1. https:\/\/doi.org\/10.1016\/j.clml.2015.02.024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5228_CR8","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/bjc.1998.216","volume":"77","author":"SM Lee","year":"1998","unstructured":"Lee SM, Radford JA, Dobson L, Huq T, Ryder WD, Pettengell R et al (1998) Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Br J Cancer 77:1294\u20131299. https:\/\/doi.org\/10.1038\/bjc.1998.216","journal-title":"Br J Cancer"},{"key":"5228_CR9","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1046\/j.1365-2141.1997.4703274.x","volume":"99","author":"DC Linch","year":"1997","unstructured":"Linch DC, Milligan DW, Winfield DA, Kelsey SM, Johnson SA, Littlewood TJ et al (1997) G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 99:933\u2013938. https:\/\/doi.org\/10.1046\/j.1365-2141.1997.4703274.x","journal-title":"Br J Haematol"},{"key":"5228_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2017.11.005","volume":"120","author":"Y Lalami","year":"2017","unstructured":"Lalami Y, Klastersky J (2017) Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol 120:163\u2013179. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.11.005","journal-title":"Crit Rev Oncol Hematol"},{"key":"5228_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3816\/SCT.2003.n.002","volume":"1","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Kuderer NM (2003) Epidemiology of febrile neutropenia. Support Cancer Ther 1:23\u201335. https:\/\/doi.org\/10.3816\/SCT.2003.n.002","journal-title":"Support Cancer Ther"},{"key":"5228_CR12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.bbmt.2017.10.026","volume":"24","author":"AD Singh","year":"2018","unstructured":"Singh AD, Parmar S, Patel K, Shah S, Shore T, Gergis U et al (2018) Granulocyte colony-stimulating factor use after autologous peripheral blood stem cell transplantation: comparison of two practices. Biol Blood Marrow Transplant 24:288\u2013293. https:\/\/doi.org\/10.1016\/j.bbmt.2017.10.026","journal-title":"Biol Blood Marrow Transplant"},{"key":"5228_CR13","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/bmt.2009.75","volume":"43","author":"M Trivedi","year":"2009","unstructured":"Trivedi M, Martinez S, Corringham S, Medley K, Ball ED (2009) Optimal use of G-CSF administration after hematopoietic SCT. Bone Marrow Transplant 43:895\u2013908. https:\/\/doi.org\/10.1038\/bmt.2009.75","journal-title":"Bone Marrow Transplant"},{"key":"5228_CR14","unstructured":"U.S. Food and Drug Administration (2015) ZARXIO\u00ae(filgrastim-sndz) injection, for subcutaneous or intravenous use: highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125553s007lbl.pdf. Accessed 14 February 2023"},{"key":"5228_CR15","unstructured":"U.S. Food and Drug Administration (2019) ZIEXTENZO\u2122 (pegfilgrastim-bmez) injection, for subcutaneous use: highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761045lbl.pdf. Accessed 14 February 2023"},{"key":"5228_CR16","unstructured":"U.S. Food and Drug Administration (2017) Biosimilar and interchangeable products. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-and-interchangeable-products. Accessed 16 December 2019"},{"key":"5228_CR17","first-page":"19","volume":"42","author":"M Awad","year":"2017","unstructured":"Awad M, Singh P, Hilas O (2017) Zarxio (Filgrastim-sndz): the first biosimilar approved by the FDA. P & T 42:19\u201323","journal-title":"P & T"},{"key":"5228_CR18","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMhle1800125","volume":"378","author":"GH Lyman","year":"2018","unstructured":"Lyman GH, Zon R, Harvey RD, Schilsky RL (2018) Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 378:2036\u20132044. https:\/\/doi.org\/10.1056\/NEJMhle1800125","journal-title":"N Engl J Med"},{"key":"5228_CR19","unstructured":"U.S. Food and Drug Administration (2010) Implementation of the biologics price competition and innovation act of 2009. https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/implementation-biologics-price-competition-and-innovation-act-2009."},{"key":"5228_CR20","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473. https:\/\/doi.org\/10.1038\/sj.leu.2404284","journal-title":"Leukemia"},{"key":"5228_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23:3\u20139. https:\/\/doi.org\/10.1038\/leu.2008.291","journal-title":"Leukemia"},{"key":"5228_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12288-018-0966-5","volume":"35","author":"V Sheth","year":"2019","unstructured":"Sheth V, Gore A, Jain R, Ghanekar A, Saikia T (2019) Pegfilgrastim: more cost effective and equally efficacious option as compared to filgrastim in autologous stem cell transplant. Indian J Hematol Blood Transfus 35:66\u201371. https:\/\/doi.org\/10.1007\/s12288-018-0966-5","journal-title":"Indian J Hematol Blood Transfus"},{"key":"5228_CR23","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3109\/10428194.2010.545462","volume":"52","author":"L Wannesson","year":"2011","unstructured":"Wannesson L, Luthi F, Zucca E, Rosselet-Christ A, Baglioni M, Marelli L et al (2011) Pegfilgrastim to accelerate neutrophil engraftment following peripheral blood stem cell transplant and reduce the duration of neutropenia, hospitalization, and use of intravenous antibiotics: a phase II study in multiple myeloma and lymphoma and comparison with filgrastim-treated matched controls. Leuk Lymphoma 52:436\u2013443. https:\/\/doi.org\/10.3109\/10428194.2010.545462","journal-title":"Leuk Lymphoma"},{"key":"5228_CR24","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1080\/16078454.2021.2003071","volume":"26","author":"X Wang","year":"2021","unstructured":"Wang X, Ren J, Liang X, He P (2021) Efficacy and cost of G-CSF derivatives for prophylaxis of febrile neutropenia in lymphoma and multiple myeloma patients underwent autologous hematopoietic stem cell transplantation. Hematology 26:950\u2013955. https:\/\/doi.org\/10.1080\/16078454.2021.2003071","journal-title":"Hematology"},{"key":"5228_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.exphem.2005.11.013","volume":"34","author":"G Vanstraelen","year":"2006","unstructured":"Vanstraelen G, Fr\u00e8re P, Ngirabacu MC, Willems E, Fillet G, Beguin Y (2006) Pegfilgrastim compared with filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp Hematol 34:382\u2013388. https:\/\/doi.org\/10.1016\/j.exphem.2005.11.013","journal-title":"Exp Hematol"},{"key":"5228_CR26","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/leu.2009.127","volume":"23","author":"S Giralt","year":"2009","unstructured":"Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL et al (2009) International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 23:1904\u20131912. https:\/\/doi.org\/10.1038\/leu.2009.127","journal-title":"Leukemia"},{"key":"5228_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5001\/omj.2019.06","volume":"34","author":"MN Hassan","year":"2019","unstructured":"Hassan MN, Fauzi HM, Husin A, Mustaffa R, Hassan R, Ibrahim MI et al (2019) Autologous peripheral blood stem cell transplantation among lymphoproliferative disease patients: factors influencing engraftment. Oman Med J 34:34\u201343. https:\/\/doi.org\/10.5001\/omj.2019.06","journal-title":"Oman Med J"},{"key":"5228_CR28","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/bcp.14226","volume":"86","author":"A Bellon","year":"2020","unstructured":"Bellon A, Wang J, Skerjanec A, Velinova M, Dickerson D, Sabet A et al (2020) A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics. Br J Clin Pharmacol 86:1139\u20131149. https:\/\/doi.org\/10.1111\/bcp.14226","journal-title":"Br J Clin Pharmacol"},{"key":"5228_CR29","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1093\/annonc\/mdx303","volume":"28","author":"K Blackwell","year":"2017","unstructured":"Blackwell K, Gascon P, Jones CM, Nixon A, Krendyukov A, Nakov R et al (2017) Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Ann Oncol 28:2272\u20132277. https:\/\/doi.org\/10.1093\/annonc\/mdx303","journal-title":"Ann Oncol"},{"key":"5228_CR30","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404. https:\/\/doi.org\/10.1186\/1471-2407-11-404","journal-title":"BMC Cancer"},{"key":"5228_CR31","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00520-014-2457-z","volume":"23","author":"AM Pfeil","year":"2015","unstructured":"Pfeil AM, Allcott K, Pettengell R, von Minckwitz G, Schwenkglenks M, Szabo Z (2015) Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Sup Care Cancer 23:525\u2013545. https:\/\/doi.org\/10.1007\/s00520-014-2457-z","journal-title":"Sup Care Cancer"},{"key":"5228_CR32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1200\/JCO.2020.39.28_suppl.299","volume":"39","author":"K Kitchen","year":"2021","unstructured":"Kitchen K, Mosier M (2021) Real-world comparison of febrile neutropenia rates with same-day versus next-day administration of pegfilgrastim. J Clin Oncol 39:299. https:\/\/doi.org\/10.1200\/JCO.2020.39.28_suppl.299","journal-title":"J Clin Oncol"},{"key":"5228_CR33","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdp576","volume":"21","author":"L Castagna","year":"2010","unstructured":"Castagna L, Bramanti S, Levis A, Michieli MG, Anastasia A, Mazza R et al (2010) Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. Ann Oncol 21:1482\u20131485. https:\/\/doi.org\/10.1093\/annonc\/mdp576","journal-title":"Ann Oncol"},{"key":"5228_CR34","first-page":"627","volume-title":"Immunomodulators. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases","author":"AV Page","year":"2020","unstructured":"Page AV, Liles WC (2020) Immunomodulators. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier, Inc, pp 627\u201354.e7"},{"key":"5228_CR35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/978-3-0348-0218-5_21","volume-title":"Twenty Years of G-CSF. Milestones in Drug Therapy","author":"TA Neumann","year":"2012","unstructured":"Neumann TA, Foote M (2012) The safety profile of filgrastim and pegfilgrastim. In: Molineux G, Foote M, Arvedson T (eds) Twenty Years of G-CSF. Milestones in Drug Therapy. Springer, Basel, pp 395\u2013408"},{"key":"5228_CR36","doi-asserted-by":"publisher","first-page":"592487","DOI":"10.3389\/fonc.2020.592487","volume":"10","author":"M Martino","year":"2020","unstructured":"Martino M, Paviglianiti A, Memoli M, Martinelli G, Cerchione C (2020) Multiple myeloma outpatient transplant program in the era of novel agents: state-of-the-art. Front Oncol 10:592487. https:\/\/doi.org\/10.3389\/fonc.2020.592487","journal-title":"Front Oncol"},{"key":"5228_CR37","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3109\/10428194.2014.931952","volume":"56","author":"M Martino","year":"2015","unstructured":"Martino M, Russo L, Martinello T, Gallo GA, Fedele R, Moscato T et al (2015) A home-care, early discharge model after autografting in multiple myeloma: results of a three-arm prospective, non-randomized study. Leuk Lymphoma 56:801\u2013804. https:\/\/doi.org\/10.3109\/10428194.2014.931952","journal-title":"Leuk Lymphoma"},{"key":"5228_CR38","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.bbmt.2014.03.027","volume":"20","author":"M Martino","year":"2014","unstructured":"Martino M, Montanari M, Ferrara F, Ciceri F, Scortechini I, Palmieri S et al (2014) Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study. Biol Blood Marrow Transplant 20:1026\u20131032. https:\/\/doi.org\/10.1016\/j.bbmt.2014.03.027","journal-title":"Biol Blood Marrow Transplant"},{"key":"5228_CR39","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1186\/s12913-022-08933-z","volume":"22","author":"GT Gebremariam","year":"2022","unstructured":"Gebremariam GT, Fentie AM, Beyene K, Sander B, Gebretekle GB (2022) Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review. BMC Health Serv Res 22:1600. https:\/\/doi.org\/10.1186\/s12913-022-08933-z","journal-title":"BMC Health Serv Res"},{"key":"5228_CR40","doi-asserted-by":"publisher","first-page":"e1139","DOI":"10.1200\/OP.20.00994","volume":"17","author":"W Wang","year":"2021","unstructured":"Wang W, Li E, Campbell K, McBride A, D'Amato S (2021) Economic analysis on adoption of biosimilar granulocyte colony-stimulating factors in patients with nonmyeloid cancer at risk of febrile neutropenia within the oncology care model framework. JCO Oncol Pract 17:e1139\u2013e1e49. https:\/\/doi.org\/10.1200\/OP.20.00994","journal-title":"JCO Oncol Pract"}],"updated-by":[{"DOI":"10.1007\/s00277-023-05323-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05228-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05228-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05228-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T09:14:13Z","timestamp":1687425253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05228-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["5228"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05228-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00277-023-05323-1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"21 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00277-023-05323-1","URL":"https:\/\/doi.org\/10.1007\/s00277-023-05323-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the International Conference on Harmonization Guidelines for Good Clinical Practice and with the 1964 Helsinki Declaration and its later amendments. The study was approved by the local institutional review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent at enrolment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants provided written informed consent for the publication of their data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All listed authors have made substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data, or the creation of new software used in the work; have drafted the work or revised it critically for important intellectual content; have approved the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}}]}}